Connor Clark & Lunn Investment Management Ltd. acquired a new stake in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 758,033 shares of the company's stock, valued at approximately $3,676,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 1.06% of Zentalis Pharmaceuticals at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Sivia Capital Partners LLC bought a new position in shares of Zentalis Pharmaceuticals in the fourth quarter worth $27,000. CTC Alternative Strategies Ltd. acquired a new position in shares of Zentalis Pharmaceuticals in the 1st quarter valued at approximately $29,000. Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals during the 2nd quarter worth approximately $37,000. Voleon Capital Management LP acquired a new stake in shares of Zentalis Pharmaceuticals during the 3rd quarter worth approximately $41,000. Finally, State of Wyoming bought a new position in Zentalis Pharmaceuticals in the first quarter valued at approximately $67,000.
Analysts Set New Price Targets
ZNTL has been the topic of several recent analyst reports. Wall Street Zen lowered Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 8th. Mizuho initiated coverage on Zentalis Pharmaceuticals in a research report on Friday, July 17th. They issued an "outperform" rating and a $8.00 target price on the stock. Rodman & Renshaw began coverage on Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They set a "buy" rating and a $11.00 target price for the company. Weiss Ratings reissued a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a report on Monday, July 6th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Four analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $6.75.
View Our Latest Stock Analysis on Zentalis Pharmaceuticals
Insider Activity at Zentalis Pharmaceuticals
In related news, major shareholder Group Walters acquired 4,335,000 shares of the stock in a transaction dated Friday, August 14th. The stock was bought at an average cost of $3.50 per share, for a total transaction of $15,172,500.00. Following the completion of the transaction, the insider directly owned 17,844,973 shares of the company's stock, valued at $62,457,405.50. The trade was a 32.09% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 3.80% of the company's stock.
Zentalis Pharmaceuticals Price Performance
NASDAQ:ZNTL opened at $3.80 on Friday. Zentalis Pharmaceuticals, Inc. has a one year low of $1.21 and a one year high of $6.95. The firm's 50 day simple moving average is $4.37 and its 200 day simple moving average is $3.72. The company has a market cap of $272.35 million, a PE ratio of -1.95 and a beta of 1.92.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). Equities research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current year.
About Zentalis Pharmaceuticals
(
Free Report)
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Featured Articles
Want to see what other hedge funds are holding ZNTL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Zentalis Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zentalis Pharmaceuticals wasn't on the list.
While Zentalis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead.
This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
